Emcure Pharma Q1FY27: 22.8% Revenue Growth, 36% PAT Rise, New Chairman
Emcure Pharmaceuticals Q1FY27: 22.8% revenue rise, 36% PAT jump, and a strong overseas drive – see the latest earnings, governance changes and AGM details.
- Emcure Pharmaceuticals Limited
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read